The content on this site is intended for healthcare professionals only
Dr Philippe Moreau, Centre Hospitalier Universitaire de Nantes, France, gives Prof Gareth Morgan, Royal Marsden Hospital, London, UK, his thoughts on the myeloma session held on the 3rd day of ASCO 2012.
He first outlines the promising results from the carfilzomib combination studies, eg, with MP and with len dex, and comments on results with the investigational oral proteasome inhibitor, MLN9708, as well as recent data with pomalidomide and panobinostat.
Dr Moreau goes on to outline initial results presented at ASCO of the bendamustine, bortezomib, dexamethasone (BVD) study in elderly patients with relapsed/refractory multiple myeloma which showed a 67% response rate in this patient group after four cycles.
This programme was made possible with an educational grant provided by Mundipharma.
SIOG 2024: Updates in haematology
Understanding the remaining unmet needs in a post ASCT NDMM setting
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Relapsed refractory multiple myeloma
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Hodgkin’s and non-Hodgkin’s lymphomas (NHL)
